FMP
Histogen Inc.
HSTO
NASDAQ
Inactive Equity
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
0.02 USD
0 (0%)
HSTO Financial Statements
Year
2022
2021
2020
2019
Current Assets
13.46M
21.61M
8.4M
2.46M
Cash & Short Term Investments
12.51M
18.68M
6.76M
2.06M
Cash And Cash Equivalents
12.11M
18.68M
6.76M
2.06M
Short Term Investments
400k
0
0
0
Net Receivables
99k
165k
144k
110k
Inventory
0
1.73M
300k
106k
Other Current Assets
767k
2.09M
1.12M
167k
Non-Current Assets
5.62M
5.64M
6.61M
484k
Property, Plant & Equipment
5.09M
4.83M
4.68M
415k
Goodwill And Intangible Assets
0
0
0
0
Goodwill
0
0
0
0
Intangible Assets
0
0
0
0
Long Term Investments
0
0
0
0
Tax Assets
0
0
0
0
Other Non-Current Assets
523k
805k
1.93M
69k
Other Assets
0
0
0
0
Total Assets
19.07M
27.25M
15.01M
2.94M
-
-
-
-
Current Liabilities
1.23M
2.33M
2.79M
1.38M
Accounts Payable
382k
1.39M
539k
808k
Short Term Debt
0
0
97k
0
Tax Payables
162k
18k
0
0
Deferred Revenue
19k
19k
48k
19k
Other Current Liabilities
426k
436k
1.43M
258k
Total Current Liabilities
1.23M
2.33M
2.79M
1.38M
Total Non-Current Liabilities
4.46M
4.73M
5.32M
39.53M
Long-Term Debt
0
0
369k
0
Deferred Revenue
79k
98k
118k
138k
Deferred Taxes Liabilities
0
0
0
0
Other Non Current liabilities
0
0
0
39.36M
Total Liabilities
5.7M
7.06M
8.1M
40.91M
Other Liabilities
0
0
0
0
Stockholders Equity
14.4M
21.19M
7.86M
-37.07M
Common Stock
5k
5k
1k
3k
Retained Earnings
-88.27M
-77.65M
-62.7M
-43.93M
Accumulated Other Comprehensive Income/Loss
0
0
-15.01M
-39.07M
Other Shareholders Equity
0
0
-15.01M
-39.07M
Total Liabilities and Stockholders Equity
19.07M
27.25M
15.01M
2.94M
Retained Earning Schedule
Year
2022
2021
2020
2019
Retained Earnings (Previous Year)
-77.65M
-62.7M
-43.93M
-186.63M
Net Income
-10.62M
-14.4M
-25.77M
-4.9M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-88.27M
-77.65M
-62.7M
-43.93M
Other Distributions
-10.62M
-14.95M
-18.77M
142.7M
PPE Schedule
Year
2022
2021
2020
2019
Gross PPE
5.09M
4.83M
4.68M
415k
Annual Depreciation
140k
97k
98k
145k
Capital Expenditure
-216k
-241k
-49k
-152k
Net PPE
5.17M
4.97M
4.63M
422k
Intangible and Goodwill Schedule
Year
2022
2021
2020
2019
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
